The European Medicines Agency has recommended for EU marketing approval six products, including as expected Clovis Oncology’s new ovarian cancer drug Rubraca (rucaparib). Among other things, the agency rejected marketing authorization applications (MAAs) for two drugs that are already approved in the US and upheld a negative opinion it adopted last December for another product.
The other five MAAs that this week received positive opinions for pan-EU approval from the EMA’s key scientific committee, the...








